Theravance drops rare disease drug after late-stage trial setback
Source: SeekingAlpha
2026-03-03 09:05:27 ET
More on Theravance Biopharma
- Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy - Slideshow
- Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript
- Seeking Alpha’s Quant Rating on Theravance Biopharma
- Historical earnings data for Theravance Biopharma
- Financial information for Theravance Biopharma
Read the full article on Seeking Alpha
For further details see:
Theravance drops rare disease drug after late-stage trial setback
Theravance Biopharma Inc.
NASDAQ: TBPH
TBPH Trading
1.07% G/L:
$14.1301 Last:
216,707 Volume:
$13.98 Open:
TBPH Latest News
TBPH Stock Data
$983,551,886
22,366,811
5.73%
43
N/A
Biotechnology & Life Sciences
Healthcare
KY
South San Francisco
